發(fā)布時(shí)間：2018-06-19 12:23

  本文選題：卵巢組織移植 + 卵巢窩�。� 參考：《首都醫(yī)科大學(xué)學(xué)報(bào)》2016年06期

【摘要】：正隨著癌癥醫(yī)學(xué)的發(fā)展,細(xì)胞毒性抗癌藥物與放射治療在臨床上的普遍應(yīng)用使癌癥患者的生存率大幅提高,如49歲以下乳腺癌患者5年生存率約90%~([1])。超過(guò)70%的年輕癌癥患者有生育要求~([2]),但性腺毒性治療會(huì)對(duì)卵巢功能造成嚴(yán)重的不可逆性損傷。例如,乳腺癌患者經(jīng)FEC或FAC方案化學(xué)藥物治療(以下簡(jiǎn)稱(chēng)化療)后,閉經(jīng)的發(fā)生率高達(dá)50%~65%~([3]),卵巢受到放射治療(≥5Gy)或經(jīng)造血干細(xì)胞移植前化
[Abstract]:With the development of cancer medicine, the general application of cytotoxic anticancer drugs and radiotherapy in clinic has greatly improved the survival rate of cancer patients, for example, the 5-year survival rate of breast cancer patients under 49 years old is about 90%. More than 70% of young cancer patients have fertility requirements, but gonadotoxic therapy can cause severe irreversible damage to ovarian function. For example, after chemotherapy with FEC or FAC regimen, the incidence of amenorrhea in breast cancer patients is as high as 500.65% (3), ovarian radiotherapy (鈮，

本文編號(hào)：2039877